5FU infusion with mitomycin-C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer.A southwest oncology group study

Autor:	Robert M. O'Bryan, Tate Thigpen, P. N. Kim, Charles A. Coltman, R. Bottomley, John D. Bonnet, Joseph D. McCracken, Carl Groppe, Frank Panettiere, Vainutis K. Vaitkevicius, Buroker T, B. Hoogstraten, Henry E. Wilson, Lance K. Heilbrun
Rok vydání:	1978
Předmět:	Oncology Cancer Research medicine.medical_specialty Group study Performance status business.industry Colorectal cancer Mitomycin C Methyl CCNU medicine.disease law.invention Bolus (medicine) Randomized controlled trial law Internal medicine Medicine In patient business
Zdroj:	Cancer. 42:1228-1233
ISSN:	1097-0142 0008-543X
DOI:	10.1002/1097-0142(197809)42:3<1228::aid-cncr2820420330>3.0.co;2-s
Popis:	The Southwest Oncology Group (SWOG) in a randomized trial evaluated 5FU infusions in combination with either Mitomycin-C or Methyl-CCNU in patients with disseminated large bowel cancer. A response rate of 18% was noted on the 5FU-Mitomycin limb as compared to 16% on the Methyl-CCNU arm (p = .39). Median survival for all treated patients was 43 weeks on both arms. Myelosuppression was found to be more significant on the Mitomycin-C arm. Regression analysis demonstrated that performance status, sex, and primary site were significant pretreatment characteristics for predicting survival. The response rates associated with this burdensome method of 5FU administration in combination with either Mitomycin-C or Methyl-CCNU appear to offer little advantage over bolus 5FU alone.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::de062e0751164d57bdbe99b1c316a36b https://doi.org/10.1002/1097-0142(197809)42:3<1228::aid-cncr2820420330>3.0.co Zobrazit plný text záznamu Plný text